The treatment of postmenopausal syndrome by monthly oral doses of quinestrol.
Seventy patients between the ages of 37 and 59 suffering from the menopausal syndrome were included in a clinical trial and treated for a period of 6 to 18 months. Out of the seventy, 43 were suffering from spontaneous and 27 from surgical menopause. Forty of them were given 1 mg of quinestrol and 30 received placebo. The drug was administered orally in a one-tablet dose once a month. An improvement took place in 35 (87.5%) of the women receiving quinestrol but in only 15 (50%) of those receiving placebo. Among the patients with spontaneous menopause an improvement was seen in 22 out of 25 (88%) receiving quinestrol, compared with 9 out of 18 (50%) receiving placebo. Tolerance of the drug was good and most of the laboratory tests as well as blood pressure and body weight showed statistically non-significant changes. This kind of treatment is expecially suitable when daily intake is undesirable.
D000284:Administration, Oral; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D009651:Norpregnatrienes / Q000627:therapeutic use*; D011800:Quinestrol / Q000008:administration & dosage / Q000627:therapeutic use*
D009651:Norpregnatrienes; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011800:Quinestrol